Melatonin ameliorates calcium homeostasis in myocardial and ischemia-reperfusion injury in chronically hypoxic rats by Yeung, HM et al.
Title Melatonin ameliorates calcium homeostasis in myocardial andischemia-reperfusion injury in chronically hypoxic rats
Author(s) Yeung, HM; Hung, MW; Fung, ML
Citation Journal Of Pineal Research, 2008, v. 45 n. 4, p. 373-382
Issued Date 2008
URL http://hdl.handle.net/10722/125089
Rights The definitive version is available atwww3.interscience.wiley.com
Melatonin ameliorates calcium homeostasis in myocardial and
ischemia–reperfusion injury in chronically hypoxic rats
Introduction
Myocardial hypoxia can be caused by ischemic hypoxia
with a local reduction of coronary blood ﬂow and by
systemic hypoxia with lowered levels of arterial oxygen. It is
well accepted that myocardial injury is closely associated
with the severity of ischemic hypoxia relevant to the clinical
manifestation of ischemic heart disease. Yet myocardial
injury, if any, caused by systemic hypoxia at moderate
levels under chronic conditions is still controversial. This
may relate to the fact that myocardial function is essentially
normal in high-altitude natives, in subjects during ascent
and sojourns at high altitudes, and in patients with chronic
obstructive pulmonary disease (COPD). Many studies have
showed that short-term hypoxia can confer cardioprotec-
tion against myocardial infarction, contractile dysfunction
and ventricular arrhythmias [1–3]. However, hypoxia in the
long term could have adverse eﬀects on myocardial
functions, particularly shown by the deterioration of
calcium (Ca2+) homeostasis in sarcoplasmic reticulum
(SR) [4, 5] and by impaired Gs(alpha) and adenylyl cyclase
intracellular signaling functions leading to altered myocar-
dial responses to beta-adrenoceptor activation [6].
Recent studies have shown that overproduction of
reactive-oxygen species (ROS) is a major mechanistic cause
of myocardial injury during ischemia/hypoxia–reperfusion
(I/R) [7–9]. Such a robust increase in cellular ROS levels
could lead to opening of mitochondrial permeability
transition pore [10, 11] and impaired intracellular Ca2+
homeostasis [12, 13]. Hence, one rationale behind pharma-
cologically induced cardioprotection against I/R injury was
to lower the ROS level during the oxidative insult.
However, it is not clear if this pharmacological strategy
could be beneﬁcial to myocardial functions under chroni-
cally hypoxic conditions.
It is well known that melatonin, as well as its metabolites
are potent antioxidants [14, 15] and melatonin is a
cardioprotective agent against I/R injuries [16–22]. The
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mechanistic eﬀect of melatonin on I/R-induced myocardial
infarction is commonly attributed to its antioxidant prop-
erties and its ability to scavenge free radical species [23–25]
while also stimulating the synthesis of antioxidant enzymes
[26–28]. Although recent studies have documented the acute
eﬀects of melatonin against myocardial I/R injury, cur-
rently there is a lack of information on the chronic eﬀect of
melatonin on myocardial functions in prolonged hypoxia
(CH). In this study, we examined the hypothesis that
chronic administration of melatonin can alleviate CH-
induced myocardial injury in rats. Results suggested that
the melatonin treatment could reduce the level of oxidative
stress and mitigate SR-Ca2+ handling in the cardiomyo-
cytes leading to improved myocardial functions in the
hypoxic rats.
Material and methods
Animals
Animal care and experimental protocol for this study were
approved by the Committee on the Use of Live Animals in
Teaching and Research of The University of Hong Kong.
The Laboratory Animal Unit of The University of Hong
Kong is fully accredited by the Association for Assessment
and Accreditation for Laboratory Animal Care (AAALAC
International). Male Sprague–Dawley rats weighing about
70 g at age 28 days were randomly divided into normoxic
and CH groups as reported previously [4–6]. While the
normoxic controls were maintained in room air, CH rats
were kept in a 300-L acrylic chamber for normobaric
hypoxia in the same room and had free access to water and
chow. The oxygen fraction inside the chamber was kept at
10 ± 0.5%, 24 hr per day. The desired oxygen content was
established by a mixture of room air and nitrogen that was
regulated and monitored by an oxygen analyzer (Vacumet-
rics Inc., CA, USA) [29]. The rats were exposed to hypoxia
for 28 days and were immediately used in the experiments.
The animal room was controlled at a constant temperature
(22 ± 2C), humidity and light:dark cycle (lights on 07:00–
19:00).
Drug preparation
Melatonin (Sigma, St. Louis, MO, USA) solution was
prepared fresh before injection by dissolving the indole-
amine in absolute ethanol and further dilution with normal
saline; the ﬁnal concentration of ethanol was 2%. As
reported previously, melatonin in 10 mg/kg body weight
[30–33] or vehicle (2% ethanol in normal saline) was
administered intraperitoneally each day. The rats were
taken out of the chamber for 30 min for the administration.
Isolated perfused heart preparation
Rats from normoxic and CH groups (both melatonin- and
vehicle-treated groups) were decapitated and the hearts
were quickly removed and placed in ice-cold Krebs–
Henseleit (K-H) perfusion buﬀer before being mounted
on the Langendorﬀ apparatus for perfusion at 37C with
K-H buﬀer at constant pressure (100 cm of H2O) and
equilibrated with 95% of O2/5% CO2. The buﬀer contained
(in mm) 118.0 NaCl, 4.7 KCl, 1.25 CaCl2, 1.2 KH2PO4, 1.2
MgSO4, 25.0 NaHCO3 and 11.0 glucose. All the hearts were
subjected to regional ischemia described previously [34, 35].
Brieﬂy, a snare was formed by placing a silk suture around
the left coronary artery of rat heart. The snare was pulled in
order to occlude the coronary artery to produce ischemia.
Reperfusion was done by releasing the snare. In this present
study, the isolated rat hearts were subjected to 30 min of
ischemia followed by 120 min of reperfusion which induced
myocardial injury.
Measurement of the area of risk
To determine the infarct size, the coronary artery was
re-occluded at the end of reperfusion and the heart was
perfused with 2.5% Evans blue to delineate the area of risk.
The hearts were frozen at )70C, cut into thin slices, which
were perpendicular to the septum, from the apex to the
base. Then incubated in sodium phosphate buﬀer contain-
ing 1% (w/v) 2,3,5-triphenyl-tetrazolium chloride for
10 min in order to visualize the unstained infarct region.
The infarct and the risk zone areas were determined by
planimetry with software Image/J from the National
Institutes of Health (Bethesda, MD). The infarct size
measured was expressed as a percentage of the risk zone.
Determination of myocardial injury by lactate
dehydrogenase (LDH) efflux
The eﬄuent from each isolated perfused rat heart was
collected at 15 min before regional ischemia, 5th min of
reperfusion and the LDH was assayed spectrophotometri-
cally by using a kit purchased from Sigma-Aldrich
(St. Louis, MO, USA). The LDH activity measured was
expressed as units per liter.
Measurement of lipid peroxidation
The lipid peroxidation was determined by using a Bioxy-
tech LPO-586 kit (OxisResearch, OR, USA). The
reaction product was measured spectrophotometrically at
586 nm. Standard curves were constructed with 1,1,3,3-
tetraethoxypropane as a standard. The level of malondial-
dehyde (MDA) in the heart is expressed as lM, while the
MDA concentration (lM) in heart was normalized to wet
tissue weight (mg) and expressed as lm/mg.
Preparation of isolated ventricular myocytes
Single ventricular myocytes were isolated from the norm-
oxic and CH rats by using a collagenase method described
previously [35, 36]. After isolation, myocytes were allowed
to stabilize for at least 30 min before any experiment.
Measurement of [Ca2+]i
A spectroﬂuorometric method with Fura-2/AM as a Ca2+
indicator was used during the measurement of [Ca2+]i.
Ventricular myocytes from either normoxic or hypoxic
rats were incubated with 5 lM Fura-2/AM for 35 min.
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Fluorescent signals obtained at 340 nm (F340) and 380 nm
(F380) excitation wavelengths were recorded and stored in
computer for data processing and analysis. The F340/F380
ratio was used to indicate cytosolic [Ca2+]i in the ventri-
cular myocytes. During the measurement of electrically
induced [Ca2+]i transients (E[Ca
2+]i), myocytes were elec-
trically stimulated at 0.2 Hz, whereas measurement of
caﬀeine-induced [Ca2+]i transients (C[Ca
2+]i) were done by
applying 10 mm caﬀeine directly to the ventricular myo-
cytes. The amplitude of E[Ca2+]i and C[Ca
2+]i were
determined as the diﬀerence between the resting and the
peak [Ca2+]i levels; the time for 50% decay of the transients
(T50) was used to represent the decay of both transients.
During the measurements, the isolated fura-2-loaded car-
diomyocytes from each group were incubated for 10 min
with non-glucose K-H solution containing 10 mm 2-deoxy-
d-glucose and 10 mm sodium dithionite to induce meta-
bolic inhibition and anoxia (MI/A). Reperfusion (MI/A-R)
was followed by incubating the myocytes with normal K-H
solution for further 10 min.
Western blotting for SERCA, RyR and NCX
Isolated cardiomyocytes from normoxic and hypoxic
groups were collected after collagenase digestion from
whole hearts. To detect the expression of SERCA2 and
RyR, SR vesicles were obtained by following procedures.
Brieﬂy, myocytes were sonicated on ice in the extraction
medium containing (in mm): 15 Tris, 10 NaHCO3, 5 NaN3,
250 sucrose and 1 EDTA (pH 7.3). The homogenate were
centrifuged for 10 min at 1000 g to remove cellular debris.
The supernatant was further centrifuged for 35 min at
20,000 g. Then the pellet was re-suspended in a mixture of
0.6 mKCl and 0.03 m histidine (pH 7.0) and centrifuged for
35 min at 20,000 g. The ﬁnal pellet was re-suspended in a
mixture of 0.25 m sucrose and 0.01 m histidine (pH 7.3) and
stored at )70C. All solutions contained three proteases
inhibitors: 1 mg/mL leupeptin, 1 mg/mL aprotinin and
1 mm phenylmethylsulfonyl ﬂuoride (PMSF). For the
measurement of NCX, puriﬁcation of plasma membrane
vesicles were carried out as described above. The pellet i.e.
sarcolemma-enriched fraction was dissolved in the lysis
buﬀer (0.6 m sucrose and 10 mm imidazole–HCl, pH 7.0)
and stored at )70C. The protein concentration of the
samples was quantiﬁed by the Bio-Rad protein assay
method by using bovine serum albumin (BSA) for the
standard curve. Sample proteins (20 lg/lane) were sepa-
rated in SDS-polyacrylamide gel (10% for SERCA and
NCX; 6% for RyR) and transferred electrophoretically to
polyvinylidene diﬂuoride membranes (0.2 lm pore size;
Bio-Rad1 ) at 4C in transfer buﬀer with glycine, Tris and
20% methanol with the Bio-Rad Trans-blot electrophoretic
transfer system. After blocking with Tris-buﬀered saline
(TBS; with Tris, NaCl and 0.2% Tween 20) containing 5%
non-fat milk, the membranes were incubated overnight at
4C with the goat anti-SERCA2a polyclonal antibody
(1:400 dilution; Santa Cruz Biotechnology, Santa Cruz,
CA, USA), mouse anti-RyR2 monoclonal antibody (1:3330
dilution; Aﬃnity BioReagent, Golden, CO, USA), mouse
anti-NCX1 monoclonal antibody (1:500 dilution; Abcam,
Cambridge, UK) and mouse anti-b-actin monoclondal
antibody (1:5000 dilution; Santa Cruz Biotechnology).
The second antibody for both protein determinations was
anti-goat or anti-mouse antibody conjugated to horse-
radish peroxidase (1:2000 dilution; Dakocytomation, Den-
mark A/S) in 5% non-fat milk TBS for 1 hr at room
temperature. The protein bands of SERCA, RyR and NCX
were detected by the chemiluminescence method (ECL
Western blotting detection; Amersham Biosciences2 ).
Statistical analysis
Values are expressed as means ± S.E.M. One-wayANOVA
(Turkeys multiple comparison test) was used to determine
the diﬀerences among the multiple groups. The signiﬁcance
level was set at P < 0.05.
Results
As shown in Fig. 1, the ratio of heart-to-body weight was
increased in the CH rats (vehicle- and melatonin-treated
Fig. 1. Ratios3 of (A) heart weight to body weight, (B) left ventricle
to right ventricle and septum, (C) hematocrit in normoxic control,
vehicle-treated (VCH) and melatonin-treated (MCH) hypoxic rats.
Values are means ± S.E.M., n = 6 rats each group. *P < 0.05
and ***P < 0.001 versus normoxic group and ###P < 0.001 ver-
sus VCH group. RV, right ventricle; LV, left ventricle; SP, septum.
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groups were, respectively, 143.8% and 125% of the
normoxic control). The ratio of left ventricular weight to
the right ventricle and septum in the vehicle-treated hypoxic
rat was increased by 10.1% of the normoxic control, but
was not diﬀerent between the melatonin-treated hypoxic rat
and the normoxic control (Fig. 1B). Hematocrit was
increased by 17.0% and 21.2%, respectively, in the vehicle-
and melatonin-treated rats, comparing with the normoxic
control (Fig. 1C).
Fig. 2 shows the MDA level in the cardiac tissue,
representing the level of lipid peroxidation under oxidative
stress. The MDA level signiﬁcantly increased in the vehicle
group, which was 313% of the normoxic control, but the
increase was much less at 25% in the melatonin group.
Before ischemia, the resting level of the LDH release
from the perfused heart of the vehicle-treated hypoxic rats
was signiﬁcantly elevated by 38.6% of the normoxic control
(Fig. 3A). There were no diﬀerences in the resting LDH
release between the melatonin-treated group and the
normoxic control, suggesting that melatonin reduced the
CH-induced myocardial injury. In addition, the LDH
release during 5 min reperfusion after ischemia was mark-
edly increased in the vehicle group (127% of the normoxic
control) but not in the melatonin-treated group (105% of
the normoxic control, Fig. 3B). Moreover, the infarct size
of the hearts in the melatonin-treated hypoxic rat (101% of
the normoxic control) was signiﬁcantly less than that of the
vehicle group (124% of the normoxic control, Fig. 3C).
Fig. 2. Levels of MDA in the rat heart in normoxic control, vehicle-
treated (VCH) and melatonin-treated (MCH) hypoxic rats. Values
are means ± S.E.M., n = 6 rats each group. ***P < 0.001 versus
normoxic group and ###P < 0.001 versus VCH group.
Fig. 3. Levels of LDH release (A) before 30-min ischemia, (B)
during 5-min of reperfusion and (C) the infarct size in rat hearts
subjected to 30-min ischemia followed by 120-min reperfusion.
Values are means ± S.E.M., n = 6 rats in each normoxic control,
vehicle-treated (VCH) and melatonin-treated (MCH) hypoxic
group. *P < 0.05 versus normoxic group and #P < 0.05 VCH
group.
Fig. 4. Levels4 of the intracellular calcium shown by ﬂuorescence
ratio (F340/F380) recorded from the isolated ventricular myocyte
before and during 10-min metabolic inhibition and anoxia (MI/A)
and 10-min reperfusion (MI/A-R). Values are means ± S.E.M.,
n = 3–4 myocytes from three to four rats in each normoxic con-
trol, vehicle-treated (VCH) and melatonin-treated (MCH) hypoxic
group. **P < 0.01 versus corresponding normoxic group;
##P < 0.01 versus corresponding VCH group; +P < 0.05 versus
corresponding group before MI/A-R.
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Before ischemia, the resting level of cytosolic calcium in
isolated cardiomyocytes was higher in the hypoxic rats
treated with vehicle than those of the melatonin-treated rats
and the normoxic control (Fig. 4). Following 10 min MI/
A-R, the calcium overloading was worsened in the vehicle
group (110% of the resting level), but was signiﬁcantly less
in the melatonin group (106% of the resting level),
compared with that of the normoxic control (107% of the
resting level).
The amplitude of caﬀeine-induced [Ca2+]i (C[Ca
2+]i)
reﬂects the Ca2+content in the SR of the cardiomyocytes
[37, 38]. Before ischemia, the C[Ca2+]i amplitude was
signiﬁcantly lowered in the vehicle-treated hypoxic rats by
36% of the normoxic control (Fig. 5A). Yet, the reduced
SR-Ca2+ content was much less in the melatonin-treated
rats, which was by 16% of the normoxic control.
Following MI/A-R, the amplitudes were decreased fur-
ther by 25% and 28% of the levels before MI/A-R,
respectively in the normoxic control and vehicle-treated
hypoxic rats. However, the decrease was less in the
hypoxic rats treated with melatonin (23% of the level
before MI/A-R), reﬂecting that SR-Ca2+ content was
better maintenance in the cardiomyocyte of CH rats with
the melatonin treatment. Furthermore, the values of T50
of C[Ca2+]i (Fig. 5B) which mainly reﬂects sarcolemmal
NCX activity during caﬀeine-induced RyR release of
Ca2+ from SR [38, 39], were not diﬀerent between the
hypoxic rats and normoxic control before ischemia. The
T50 values were signiﬁcantly increased in all groups
following M I/A-R but the increases were not diﬀerent
among the hypoxic rats and the normoxic control.
The amplitude of electrically induced [Ca2+]i transients
(E[Ca2+]i) reﬂects the Ca
2+ release during excitation–
contraction (E-C) coupling and directly correlates with
shortening in rat cardiomyocytes [4, 40]. Before ischemia,
the amplitude of E[Ca2+]i was signiﬁcantly lowered in the
vehicle-treated hypoxic rats by 43.3% of the normoxic
control (Fig. 6A). The lowered E[Ca2+]i level was much less
in the hypoxic rats treated with melatonin, which was
20.0% of the normoxic control. The values of the ampli-
tudes in all rat groups were signiﬁcantly reduced during 1–
3 min of ischemia–reperfusion with elevated ROS levels
[41]. The amplitude of the E[Ca
2+]i in the melatonin-treated
rats was signiﬁcantly greater than that of vehicle group. In
addition, before ischemia the decay time (T50) of E[Ca
2+]i
(Fig. 6B) which represents mainly the Ca2+ reuptake to SR
via SERCA (>90% Ca2+ in cytoplasm) and partly the
extrusion to extracellular space by NCX [42, 43], was longer
in the hypoxic rats than that of the normoxic group (by
37% and 23%, respectively, in vehicle- and melatonin-
treated rats). During MI/A-R, the values were markedly
prolonged in the normoxic control (121% of that before
MI/A-R). However, the increase in T50 value was signiﬁ-
cantly less in the melatonin-treated rats (13% of that before
MI/A-R) than that of the hypoxic rats treated with vehicle
(23% of that before MI/A-R). Moreover, the time to peak
of E[Ca2+]i (Fig. 6C) which indicates the speed of Ca
2+
release via RyR of SR [6], was not diﬀerent between the
(A) (B)Fig. 5. (A) Amplitude and (B) decay time
of caﬀeine-induced calcium transients in
the cardiomyocyte before and during
10-min MI/A-R. Values are means ±
S.E.M., n = 3–4 myocytes from three to
four rats in each normoxic control, vehi-
cle-treated (VCH) and melatonin-treated
(MCH) hypoxic group. *P < 0.05,
**P < 0.01 versus corresponding norm-
oxic group; #P < 0.05 versus corre-
sponding VCH group; +P < 0.05 versus
corresponding group before MI/A-R.
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hypoxic and normoxic groups before MI/A. During MI/
A-R, the value was markedly increased in the normoxic
group (9% of the level before MI/A-R) but the increase was
not diﬀerent from the melatonin-treated hypoxic rats.
The cardiac SERCA2a expression (Fig. 7A) was sharply
decreased in the vehicle-treated hypoxic rats by 53% of the
normoxic control. The reduced expression was signiﬁcantly
less in the hypoxic rats treated with melatonin, which was
by 18.8% of the normoxic control. Yet, levels of the protein
expression of Na+/Ca2+ exchanger (NCX1) (Fig. 7B) and
ryanodine receptor (RyR2) (Fig. 7C) in CH rat hearts were
not diﬀerent from those of the normoxic control.
Discussion
The major ﬁnding of this study is that melatonin markedly
lowered the levels of oxidative stress, [Ca2+]i overload and
I/R injury in the myocardium by ameliorating SERCA
expression and function for the calcium handling in the SR
of cardiomyocytes in CH rats. Results support the conten-
tion that antioxidant melatonin and/or its metabolites are
cardioprotective against CH-induced myocardial injury.
In consistent to our previous ﬁndings [4–6], the CH heart
was hypertrophied with diminished [Ca2+]i handling, which
imitates the pathogenic development of heart failure. In this
study, we found that melatonin treatment was signiﬁcant in
reducing the myocardial injury in CH rats. Hence, levels of
the cardiac hypertrophy and resting LDH release were
markedly lowered by melatonin treatment in the hypoxic
rats. This is likely to be explained by the fact that the level
of oxidative stress shown by the MDA level in the cardiac
tissue of the melatonin-treated rat was not diﬀerent
from the normoxic control, strongly suggesting a free
radical scavenging mechanism mediated by the antioxidant
property of melatonin.
Previous studies have reported that melatonin is a cardio-
protective agent against myocardial and I/R injuries [16–20,
44]. Multiple mechanisms could explain the antioxidant
property of melatonin, including by scavenging oxygen-
based free radicals directly [15, 45–49] or indirectly by
stimulating antioxidant enzymes [50, 51] and increasing
mitochondrial oxidative phosphorylation to lower free
radical generations [45, 52–55]. We found that melatonin
not only reduced MDA levels, but also lowered the LDH
release and infarct size induced by I/R in the CH rat heart.
This observation was anticipated because melatonin treat-
ment lessened the oxidative stress in the CH heart and this
might improve cardiac tolerance against the oxidative injury
induced by ROS overproduction during I/R [56–58]. These
results support the idea that the administration of melatonin
couldbe apreventive treatment for theworseningmyocardial
function and injury under CH conditions.
(A) (B)
(C)
Fig. 6. (A) Amplitude, (B) decay time and
(C) time-to-peak of electrically induced
calcium transients in the cardiomyocyte
before and during 10-min MI/A-R. Values
are means ± S.E.M., n = 3–4 myocytes
from three to four rats in each normoxic
control, vehicle-treated (VCH) and mela-
tonin-treated (MCH) hypoxic group.
*P < 0.05, **P < 0.01 versus corre-
sponding normoxic group; #P < 0.05 and
##P < 0.01 versus corresponding VCH
group; +P < 0.05 versus corresponding
group before MI/A-R.
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For the cellular and molecular alterations in the patho-
genesis of a failing heart, it is well known that Ca2+ plays
an important role in maintaining cardiac functions. The SR
and sarcolemma of the cardiomyocytes are major compo-
nents of normal Ca2+ homeostasis in the heart [59]. When
the depolarization of the action potential activates L-type
Ca2+ channels, Ca2+ inﬂux occurs to increase [Ca2+]i
levels. A small rise in [Ca2+]i triggers Ca
2+ release from SR
via RyR, by the process known as Ca2+-induced Ca2+
release [60]. During relaxation, most of the Ca2+ released is
sequestered by the SR via SERCA and partly extruded out
of the cell via the sarcolemmal sodium calcium exchange
(NCX). It has been shown that I/R impairs SR function by
depressing phosphorylation of SR Ca2+ handling proteins
[61–63] and results in impaired Ca2+ homeostasis leading
to [Ca2+]i overload and damaging myocardial contractility
in rat cardiomyocytes [64–66]. In agreement with our
previous ﬁndings [6], CH signiﬁcantly lowered the ampli-
tudes of caﬀeine- and electrically induced [Ca2+]i, suggest-
ing decreased SR Ca2+ content and contractility in CH rat
cardiomyocytes.
Moreover, we demonstrated that during MI/A-R, the
impaired Ca2+ homeostasis in CH rat cardiomyocytes was
more severe with elevated [Ca2+]i overloading level and
prolonged decay time (T50) of E[Ca
2+]i, indicating deteri-
oration of SR-Ca2+ re-uptake in the CH rat cardiomyo-
cyte. Thus, the alterations in the SR-Ca2+ handling and
Ca2+ homeostasis underlying the CH-induced myocardial
injury were in parallel to those induced by I/R, but rather
developed in a progressive manner under CH conditions.
Importantly, melatonin preserved the SR-Ca2+ content
and improved contractility in the CH rat cardiomyocyte.
Furthermore, the protective eﬀect of melatonin was also
eﬀective against the additional oxidative insult imposed by
MI/A-R, which are essential to the increased myocardial
tolerance against I/R injury. This is in consistent with
ﬁndings in previous studies suggesting that impaired
myocardial and calcium handing functions are improved
by the melatonin treatment [16–20, 67].
To address whether alterations in the expression of Ca2+
handling proteins of SR and sarcolemma may account for
the ameliorated Ca2+ homeostasis in the CH rat cardio-
myocytes, we examined the protein expression of the
SERCA, RyR and NCX. Our results showed that the
protein expression of SERCA, but not RyR nor NCX, was
signiﬁcantly attenuated in the CH rat heart, supporting that
lowered SR Ca2+ re-uptake causes the decreased SR-Ca2+
content and impaired Ca2+ homeostasis. This downregu-
lation of the SERCA expression was not observed in the
CH rats treated with melatonin, showing that the mecha-
nistic eﬀect on the ameliorated SR-Ca2+ re-uptake and
Ca2+ homeostasis could be mediated by a transcriptional
regulation of the SERCA expression. Yet, the involvement
of antioxidant eﬀect of melatonin in the mechanistic detail
of the SERCA regulation awaits further investigation.
In conclusion, we have shown that melatonin was
cardioprotective against CH-induced myocardial injury.
Numerous other studies have also documented melatonins
cardioprotective actions under a variety of diﬀerent situa-
tions [68]. Based on current ﬁndings, we proposed that
the administration of melatonin could be a preventive
approach to alleviate the oxidative stress in the heart under
(A)
(C)
(B)
Fig. 7. Levels of the protein expression of (A) SERCA2, (B) NCX1 and (C) RyR2 in the rat heart of normoxic control, vehicle-treated
(VCH) and melatonin-treated (MCH) hypoxic rats. Values are means ± S.E.M., n = 6 rats in each group. *P < 0.05 and ***P < 0.001
versus normoxic group and ###P < 0.001 versus VCH group.
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CH conditions, which is a major pathogenic cause of the
alterations in myocardial function leading to subsequent
injury and lowered tolerance to I/R injury. The fact that
chronic melatonin treatment mitigates the SR-Ca2+ han-
dling and Ca2+ homeostasis in the cardiomyocyte under
CH conditions, addresses the cellular mechanism for the
cardioprotective eﬀect of melatonin. In addition, the
regulation of SERCA expression is involved in the mech-
anistic eﬀect of melatonin on the improved myocardial
function in CH, thus, functionally important for maintain-
ing the replenishment of SR-Ca2+ content and preventing
the [Ca2+]i overload. This provides a cellular basis for the
better maintenance of Ca2+ homeostasis and contractility
in cardiomyocytes under CH conditions and also the
tolerance to I/R-induced myocardial injuries.
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